Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?

Area of Science:

• * Infectious Diseases
• * Vaccinology
• * Public Health

Background:

• * Meningococcal disease, particularly sepsis and meningitis, poses a significant health threat, especially to infants, children, and young adults.
• * While vaccines exist for groups A, C, W, and Y, protection against group B (MenB) strains was limited until the development of the 4-component group B vaccine (4CMenB).
• * 4CMenB has been utilized in outbreak responses and for at-risk populations, including large-scale interventions in the US and Canada.

Purpose of the Study:

• * To detail the recommendation and implementation of the 4CMenB vaccine into the UK infant immunization schedule.
• * To highlight the integration of prophylactic paracetamol with 4CMenB administration to manage potential fever side effects.
• * To emphasize the importance of post-implementation surveillance for gathering vaccine efficacy data.

Main Methods:

• * Review of clinical data supporting the use of prophylactic paracetamol with 4CMenB to mitigate fever.
• * Description of the UK's recommendation for 4CMenB in infants at 2, 4, and 12 months of age, alongside routine immunizations.
• * Discussion of the procurement process and timeline leading to vaccine implementation.

Main Results:

• * The UK recommended 4CMenB for infants, with a strategy including prophylactic paracetamol to manage fever.
• * Paracetamol administration was shown to reduce fever rates to baseline levels without compromising vaccine immunogenicity.
• * Implementation into the UK schedule faced delays due to procurement discussions.

Conclusions:

• * The 4CMenB vaccine is a crucial tool for preventing meningococcal B disease in infants.
• * Co-administration of prophylactic paracetamol with 4CMenB is a recommended practice to improve tolerability.
• * Ongoing surveillance is essential to evaluate the real-world effectiveness of 4CMenB in preventing MenB cases.